645 related articles for article (PubMed ID: 12230594)
21. Feverfew for preventing migraine.
Pittler MH; Ernst E
Cochrane Database Syst Rev; 2004; (1):CD002286. PubMed ID: 14973986
[TBL] [Abstract][Full Text] [Related]
22. Randomised double-blind placebo-controlled trial of feverfew in migraine prevention.
Murphy JJ; Heptinstall S; Mitchell JR
Lancet; 1988 Jul; 2(8604):189-92. PubMed ID: 2899663
[TBL] [Abstract][Full Text] [Related]
23. [Studies on the antimigraine action of Feverfew (Tanacetum parthenium (L.) Sch. Bip.)].
Studzińska-Sroka E; Znajdek-Awizeń P; Gawron-Gzella A
Wiad Lek; 2013; 66(2 Pt 2):195-9. PubMed ID: 25775817
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: data from two randomized, double-blind, placebo-controlled studies.
Mannix LK; Savani N; Landy S; Valade D; Shackelford S; Ames MH; Jones MW
Headache; 2007; 47(7):1037-49. PubMed ID: 17635595
[TBL] [Abstract][Full Text] [Related]
25. Randomized, double-blind, placebo-controlled, proof-of-concept study of the cortical spreading depression inhibiting agent tonabersat in migraine prophylaxis.
Goadsby PJ; Ferrari MD; Csanyi A; Olesen J; Mills JG;
Cephalalgia; 2009 Jul; 29(7):742-50. PubMed ID: 19222510
[TBL] [Abstract][Full Text] [Related]
26. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
Dodick DW; Turkel CC; DeGryse RE; Aurora SK; Silberstein SD; Lipton RB; Diener HC; Brin MF;
Headache; 2010 Jun; 50(6):921-36. PubMed ID: 20487038
[TBL] [Abstract][Full Text] [Related]
27. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
Aurora SK; Winner P; Freeman MC; Spierings EL; Heiring JO; DeGryse RE; VanDenburgh AM; Nolan ME; Turkel CC
Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197
[TBL] [Abstract][Full Text] [Related]
28. Randomized, double-blind, placebo-controlled, phase II trial of gabapentin enacarbil for migraine prophylaxis.
Silberstein S; Goode-Sellers S; Twomey C; Saiers J; Ascher J
Cephalalgia; 2013 Jan; 33(2):101-11. PubMed ID: 23165696
[TBL] [Abstract][Full Text] [Related]
29. Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. The Diclofenac-K/Sumatriptan Migraine Study Group.
Cephalalgia; 1999 May; 19(4):232-40. PubMed ID: 10376168
[TBL] [Abstract][Full Text] [Related]
30. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs.
Dodick DW; Freitag F; Banks J; Saper J; Xiang J; Rupnow M; Biondi D; Greenberg SJ; Hulihan J;
Clin Ther; 2009 Mar; 31(3):542-59. PubMed ID: 19393844
[TBL] [Abstract][Full Text] [Related]
31. Topiramate for migraine prevention in a naturalistic setting: results from an open label, flexible dose study.
Nelles G; Delbrück A; Schulze L; Kademann B; Bornhoevd K; Schäfer S; Schäuble B;
Headache; 2009; 49(10):1454-65. PubMed ID: 19804392
[TBL] [Abstract][Full Text] [Related]
32. Safety and tolerability of short-term preventive frovatriptan: a combined analysis.
MacGregor EA; Brandes JL; Silberstein S; Jeka S; Czapinski P; Shaw B; Pawsey S
Headache; 2009 Oct; 49(9):1298-314. PubMed ID: 19788471
[TBL] [Abstract][Full Text] [Related]
33. Feverfew for migraine prophylaxis: a systematic review.
Saranitzky E; White CM; Baker EL; Baker WL; Coleman CI
J Diet Suppl; 2009; 6(2):91-103. PubMed ID: 22435410
[TBL] [Abstract][Full Text] [Related]
34. Cyclandelate in the prophylaxis of migraine: a placebo-controlled study.
Diener HC; Krupp P; Schmitt T; Steitz G; Milde K; Freytag S
Cephalalgia; 2001 Feb; 21(1):66-70. PubMed ID: 11298666
[TBL] [Abstract][Full Text] [Related]
35. [Feverfew as a prophylactic treatment of migraine].
Prusiński A; Durko A; Niczyporuk-Turek A
Neurol Neurochir Pol; 1999; 33 Suppl 5():89-95. PubMed ID: 10719691
[TBL] [Abstract][Full Text] [Related]
36. Memantine for Prophylactic Treatment of Migraine Without Aura: A Randomized Double-Blind Placebo-Controlled Study.
Noruzzadeh R; Modabbernia A; Aghamollaii V; Ghaffarpour M; Harirchian MH; Salahi S; Nikbakht N; Noruzi N; Tafakhori A
Headache; 2016 Jan; 56(1):95-103. PubMed ID: 26638119
[TBL] [Abstract][Full Text] [Related]
37. Topiramate for migraine prevention: a randomized controlled trial.
Brandes JL; Saper JR; Diamond M; Couch JR; Lewis DW; Schmitt J; Neto W; Schwabe S; Jacobs D;
JAMA; 2004 Feb; 291(8):965-73. PubMed ID: 14982912
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and tolerability of topiramate 200 mg/d in the prevention of migraine with/without aura in adults: a randomized, placebo-controlled, double-blind, 12-week pilot study.
Silberstein SD; Hulihan J; Karim MR; Wu SC; Jordan D; Karvois D; Kamin M
Clin Ther; 2006 Jul; 28(7):1002-11. PubMed ID: 16990078
[TBL] [Abstract][Full Text] [Related]
39. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study.
Dodick DW; Mauskop A; Elkind AH; DeGryse R; Brin MF; Silberstein SD;
Headache; 2005 Apr; 45(4):315-24. PubMed ID: 15836567
[TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study.
Dodick DW; Goadsby PJ; Spierings EL; Scherer JC; Sweeney SP; Grayzel DS
Lancet Neurol; 2014 Sep; 13(9):885-92. PubMed ID: 25127173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
